OsteoGeneX is developing a first in class bone building small molecule against the validated target Sclerostin.
OsteoGeneX possesses both near term accelerated clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics.
OsteoGeneX’s proprietary development approach lends itself to a safe therapeutic - with less human adverse effects in clinical trials.
OsteoGeneX’s therapeutics outperform the current standard of care (antiresorptives) by acting directly on the bone cell to result in a controlled double digit bone density increase to quickly re-‐establish and maintain normal healthy bone levels. Antiresorptives work by stopping bone loss and only result in a small single digit increase in bone density during the first year of therapy only.